B-Cell Non-Hodgkin Lymphoma ' Pipeline Review, H1 2013

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

B-Cell Non-Hodgkin Lymphoma ' Pipeline Review, H1 2013
Published on February 2013

Report Summary


Summary

Global Markets Direct's, 'B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication's
therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete
with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the
therapeutic development for B-Cell Non-Hodgkin Lymphoma. B-Cell Non-Hodgkin Lymphoma - Pipeline Review, Half Year is built
using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings,
investor presentations and featured press releases from company/university sites and industry-specific third party sources, put
together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for B-Cell Non-Hodgkin Lymphoma.
- A review of the B-Cell Non-Hodgkin Lymphoma products under development by companies and universities/research institutes
based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the B-Cell Non-Hodgkin Lymphoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for B-Cell Non-Hodgkin Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding B-Cell Non-Hodgkin Lymphoma pipeline depth and focus of
Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

B-Cell Non-Hodgkin Lymphoma ' Pipeline Review, H1 2013 (From Slideshare) Page 1/10


Table of Content

Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
B-Cell Non-Hodgkin Lymphoma Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for B-Cell Non-Hodgkin Lymphoma 13
B-Cell Non-Hodgkin Lymphoma Therapeutics under Development by Companies 15
B-Cell Non-Hodgkin Lymphoma Therapeutics under Investigation by Universities/Institutes 21
Late Stage Products 25
Comparative Analysis 25
Mid Clinical Stage Products 26
Early Clinical Stage Products 27
Discovery and Pre-Clinical Stage Products 28
B-Cell Non-Hodgkin Lymphoma Therapeutics ' Products under Development by Companies 29
B-Cell Non-Hodgkin Lymphoma Therapeutics ' Products under Investigation by Universities/Institutes 37
Companies Involved in B-Cell Non-Hodgkin Lymphoma Therapeutics Development 41
Bristol-Myers Squibb Company 41
Johnson & Johnson 42
F. Hoffmann-La Roche Ltd. 43
Kyowa Hakko Kirin Co., Ltd. 44
Biogen Idec Inc. 45
Amgen Inc. 46
Sanofi-Aventis 47
AstraZeneca PLC 48
Eli Lilly and Company 49
GlaxoSmithKline plc 50
Seattle Genetics, Inc. 51
Genentech, Inc. 52
MedImmune LLC 53
Gilead Sciences, Inc. 54
Merck & Co., Inc. 55
Emergent BioSolutions Inc. 56
Infinity Pharmaceuticals, Inc. 57
Reliance Life Sciences Pvt. Ltd. 58
Celltrion, Inc. 59
Millennium Pharmaceuticals, Inc. 60
Novartis AG 61



Astellas Pharma Inc. 62
Biocon Limited 63
Ono Pharmaceutical Co., Ltd. 64
Pfizer Inc. 65
SuperGen, Inc. 66
Teva Pharmaceutical Industries Limited 67
Cell Therapeutics, Inc. 68
Genmab A/S 69
Sandoz Inc. 70
Celgene Corporation 71
Onyx Pharmaceuticals, Inc. 72
Bayer AG 73
Merck KGaA 74
Celldex Therapeutics, Inc. 75
AEterna Zentaris Inc. 76
IMMUNOMEDICS, INC 77
MethylGene Inc 78
Curis, Inc. 79
Accentia Biopharmaceuticals, Inc. 80
Portola Pharmaceuticals, Inc. 81
Telik, Inc. 82
Pharmacyclics, Inc. 83
Spectrum Pharmaceuticals, Inc. 84
Memgen, LLC. 85
Ascenta Therapeutics, Inc. 86
Provenance Biopharmaceuticals Corp. 87
Semafore Pharmaceuticals, Inc. 88
Stemline Therapeutics, Inc. 89
Onconova Therapeutics, Inc 90
Immune System Therapeutics Ltd. 91
CureTech Ltd. 92
Cylene Pharmaceuticals, Inc. 93
Cancer Therapeutics CRC Pty Ltd 94
Areta International s.r.l. 95
Helmholtz Zentrum München, GmbH 96
Synthon BV 97
Shanghai CP Guojian Pharmaceutical Co.,Ltd. 98
PharmaTech International, Inc. 99
Cell>Point 100
Advancell 101
B-Cell Non-Hodgkin Lymphoma ' Therapeutics Assessment 102
Assessment by Monotherapy Products 102
Assessment by Combination Products 103
Assessment by Route of Administration 104
Assessment by Molecule Type 106
Drug Profiles 109
perifosine - Drug Profile 109
obinutuzumab - Drug Profile 112



obinutuzumab - Drug Profile 114
AT-7519 - Drug Profile 162
bevacizumab - Drug Profile 164
bortezomib - Drug Profile 168
DI-Leu16-IL2 - Drug Profile 180
MDX-1097 - Drug Profile 181
carfilzomib - Drug Profile 182
everolimus - Drug Profile 185
idelalisib - Drug Profile 188
idelalisib - Drug Profile 190
ISF-35 - Drug Profile 192
canfosfamide hydrochloride - Drug Profile 194
SF-1126 - Drug Profile 198
SL-101 - Drug Profile 200
ON-013105 - Drug Profile 201
pralatrexate - Drug Profile 202
MLN-0128 - Drug Profile 205
etoposide + [cyclophosphamide] + [rituximab] + Radioimmunotherapy - Drug Profile 282
bortezomib + [valacyclovir hydrochloride] + [rituximab] - Drug Profile 284
bortezomib + [rituximab] - Drug Profile 285
ofatumumab + [bendamustine hydrochloride] - Drug Profile 286
palbociclib + [bortezomib] - Drug Profile 287
ofatumumab + [cyclophosphamide] + [doxorubicin] + [prednisone] [INN] + [vincristine sulfate] - Drug Profile 288
rituximab - Drug Profile 290
epratuzumab + [rituximab] - Drug Profile 293
veltuzumab + yttrium y 90 epratuzumab tetraxetan - Drug Profile 295
milatuzumab + veltuzumab - Drug Profile 296
ocaratuzumab - Drug Profile 297
rituximab biosimilar + [cyclophosphamide] + [doxorubicin] + [prednisone] + [vincristine sulfate] - Drug Profile 299
DHAP + Rituximab - Drug Profile 301
Therapeutic tumor infiltrating lymphocytes program - Drug Profile 302
Therapeutic tumor infiltrating lymphocytes program - Drug Profile 304
bortezomib + [cyclophosphamide] + [prednisone] + [rituximab] + [vincristine sulfate] - Drug Profile 306
AVL-292 - Drug Profile 308
lenalidomide + rituximab - Drug Profile 310
cytarabine + doxorubicin + Radioimmunotherapy - Drug Profile 311
bortezomib + [dexamethasone acetate] + [rituximab] - Drug Profile 313
denileukin diftitox + [rituximab] - Drug Profile 315
ofatumumab + [cyclophosphamide] + [doxorubicin] + [prednisone] + [vincristine sulfate] - Drug Profile 316
Rituximab + Cyclophosphamide + Bortezomib + Dexamethasone - Drug Profile 318
lenalidomide + [rituximab] - Drug Profile 319
bortezomib + [rituximab] - Drug Profile 320
IPI-145 - Drug Profile 321
CX-5461 - Drug Profile 323
AT-9283 + [docetaxel] - Drug Profile 325
MK-2206 - Drug Profile 326



EMD-521873 - Drug Profile 328
rituximab biosimilar - Drug Profile 330
RG-7593 - Drug Profile 332
Tumor Antigens + Autologous Dendritic Cells - Drug Profile 334
CUDC-907 - Drug Profile 335
Rituximab Biosimilar - Drug Profile 336
bortezomib + temsirolimus - Drug Profile 337
RG-7596 - Drug Profile 338
ibritumomab tiuxetan + [rituximab] - Drug Profile 339
TRU-016 + [bendamustine hydrochloride] + [rituximab] - Drug Profile 341
bortezomib + [cyclophosphamide] + [doxorubicin] + [prednisone] + [rituximab] + [vincristine sulfate] - Drug Profile 343
ABT-199 - Drug Profile 344
PRT-2070 - Drug Profile 346
MK-8808 + [cyclophosphamide] + [vincristine sulfate] + [prednisolone] - Drug Profile 347
Rituximab Biosimilar - Drug Profile 349
ARN-3015 - Drug Profile 350
SAR-245409 + [rituximab] - Drug Profile 351
SAR-245409 + [bendamustine hydrochloride] + [rituximab] - Drug Profile 352
SAR-245409 + [bendamustine hydrochloride] - Drug Profile 353
Lenalidomide + Rituximab + Bendamustine - Drug Profile 354
rituximab biosimilar + [cyclophosphamide] + [doxorubicin] + [prednisone] + [vincristine sulfate] - Drug Profile 356
SAR-3419 + [rituximab] - Drug Profile 357
Platinum-EC-G - Drug Profile 358
187 Re-EC-G - Drug Profile 359
CMC-544 + CCI-779 - Drug Profile 360
ibrutinib + [rituximab] + [cyclophosphamide] + doxorubicin + vincristine + prednisone - Drug Profile 361
Drug Targeting PRMT5 - Drug Profile 363
ONO-4059 - Drug Profile 364
Anti-CD 19 CAR Autologous PBL - Drug Profile 365
ATRA For Mantle Cell Lymphoma - Drug Profile 366
131I-Rituximab - Drug Profile 367
Bendamustine + Rituximab + 90Y Labelled Iburitumomab Tiuxetan - Drug Profile 368
Rituximab + Cytarabine + Dexamethasone + Bortezomib - Drug Profile 369
BCL-6 Inhibitor - Drug Profile 371
Carfilzomib + Dexamethasone + Rituximab - Drug Profile 372
Recombinant Idiotypic VK3-20 Vaccine - Drug Profile 373
Multiple Lead Series Targeting IRAK4 - Drug Profile 374
ND-2110 - Drug Profile 375
ND-2158 - Drug Profile 377
Andrographolide - Drug Profile 379
pecazine - Drug Profile 380
thioridazine - Drug Profile 381
B-Cell Non-Hodgkin Lymphoma Therapeutics ' Drug Profile Updates 382
B-Cell Non-Hodgkin Lymphoma Therapeutics ' Discontinued Products 487
B-Cell Non-Hodgkin Lymphoma Therapeutics - Dormant Products 489
B-Cell Non-Hodgkin Lymphoma ' Product Development Milestones 495
Featured News & Press Releases 495
Appendix 503



Methodology 503
Coverage 503
Secondary Research 503
Primary Research 503
Expert Panel Validation 503
Contact Us 504
Disclaimer 504

List of Tables

Number of Products Under Development for B-Cell Non-Hodgkin Lymphoma, H1 2013 24
Products under Development for B-Cell Non-Hodgkin Lymphoma ' Comparative Analysis, H1 2013 25
Number of Products under Development by Companies, H1 2013 27
Number of Products under Development by Companies, H1 2013 (Contd..1) 28
Number of Products under Investigation by Universities/Institutes, H1 2013 33
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 34
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 35
Comparative Analysis by Late Stage Development, H1 2013 36
Comparative Analysis by Mid Clinical Stage Development, H1 2013 37
Comparative Analysis by Early Clinical Stage Development, H1 2013 38
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 39
Products under Development by Companies, H1 2013 40
Products under Development by Companies, H1 2013 (Contd..1) 41
Products under Investigation by Universities/Institutes, H1 2013 48
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 49
Bristol-Myers Squibb Company, H1 2013 52
Johnson & Johnson, H1 2013 53
F. Hoffmann-La Roche Ltd., H1 2013 54
Kyowa Hakko Kirin Co., Ltd., H1 2013 55
Biogen Idec Inc., H1 2013 56
Amgen Inc., H1 2013 57
Sanofi-Aventis, H1 2013 58
AstraZeneca PLC, H1 2013 59
Eli Lilly and Company, H1 2013 60
GlaxoSmithKline plc, H1 2013 61



Seattle Genetics, Inc., H1 2013 62
Genentech, Inc., H1 2013 63
MedImmune LLC, H1 2013 64
Gilead Sciences, Inc., H1 2013 65
Merck & Co., Inc., H1 2013 66
Emergent BioSolutions Inc., H1 2013 67
Infinity Pharmaceuticals, Inc., H1 2013 68
Reliance Life Sciences Pvt. Ltd., H1 2013 69
Celltrion, Inc., H1 2013 70
Millennium Pharmaceuticals, Inc., H1 2013 71
Novartis AG, H1 2013 72
Astellas Pharma Inc., H1 2013 73
Biocon Limited, H1 2013 74
Ono Pharmaceutical Co., Ltd., H1 2013 75
Pfizer Inc., H1 2013 76
SuperGen, Inc., H1 2013 77
Teva Pharmaceutical Industries Limited, H1 2013 78
Cell Therapeutics, Inc., H1 2013 79
Genmab A/S, H1 2013 80
Sandoz Inc., H1 2013 81
Celgene Corporation, H1 2013 82
Onyx Pharmaceuticals, Inc., H1 2013 83
Bayer AG, H1 2013 84
Merck KGaA, H1 2013 85
Celldex Therapeutics, Inc., H1 2013 86
AEterna Zentaris Inc., H1 2013 87
IMMUNOMEDICS, INC, H1 2013 88
MethylGene Inc, H1 2013 89
Curis, Inc., H1 2013 90
Accentia Biopharmaceuticals, Inc., H1 2013 91
Portola Pharmaceuticals, Inc., H1 2013 92
Telik, Inc., H1 2013 93
Pharmacyclics, Inc., H1 2013 94
Spectrum Pharmaceuticals, Inc., H1 2013 95
Memgen, LLC., H1 2013 96
Ascenta Therapeutics, Inc., H1 2013 97
Provenance Biopharmaceuticals Corp., H1 2013 98
Semafore Pharmaceuticals, Inc., H1 2013 99
Stemline Therapeutics, Inc., H1 2013 100
Onconova Therapeutics, Inc, H1 2013 101
Immune System Therapeutics Ltd., H1 2013 102
CureTech Ltd., H1 2013 103
Cylene Pharmaceuticals, Inc., H1 2013 104
Cancer Therapeutics CRC Pty Ltd, H1 2013 105
Areta International s.r.l., H1 2013 106
Helmholtz Zentrum München, GmbH, H1 2013 107
Synthon BV, H1 2013 108
Shanghai CP Guojian Pharmaceutical Co.,Ltd., H1 2013 109



PharmaTech International, Inc., H1 2013 110
Cell>Point, H1 2013 111
Advancell, H1 2013 112
Assessment by Monotherapy Products, H1 2013 113
Assessment by Combination Products, H1 2013 114
Assessment by Stage and Route of Administration, H1 2013 116
Assessment by Stage and Molecule Type, H1 2013 119
B-Cell Non-Hodgkin Lymphoma Therapeutics ' Drug Profile Updates 393
B-Cell Non-Hodgkin Lymphoma Therapeutics ' Discontinued Products 498
B-Cell Non-Hodgkin Lymphoma Therapeutics ' Discontinued Products (Contd..1) 499
B-Cell Non-Hodgkin Lymphoma Therapeutics ' Dormant Products 500
B-Cell Non-Hodgkin Lymphoma Therapeutics ' Dormant Products (Contd..1) 501

List of Figures

Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H1 2013 24
Products under Development for B-Cell Non-Hodgkin Lymphoma ' Comparative Analysis, H1 2013 25
Products under Development by Companies, H1 2013 26
Products under Investigation by Universities/Institutes, H1 2013 32
Late Stage Products, H1 2013 36
Mid Clinical Stage Products, H1 2013 37
Early Clinical Stage Products, H1 2013 38
Discovery and Pre-Clinical Stage Products, H1 2013 39
Assessment by Monotherapy Products, H1 2013 113
Assessment by Combination Products, H1 2013 114
Assessment by Route of Administration, H1 2013 115
Assessment by Stage and Route of Administration, H1 2013 116
Assessment by Molecule Type, H1 2013 117
Assessment by Stage and Molecule Type, H1 2013 118


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


B-Cell Non-Hodgkin Lymphoma ' Pipeline Review, H1 2013

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

B-Cell Non-Hodgkin Lymphoma ' Pipeline Review, H1 2013